DCTH Insider Trading (Delcath Systems)
Insider Ownership Percentage: 16.76%
Insider Buying (Last 12 Months): $585,884.72
Insider Selling (Last 12 Months): $0.00
Delcath Systems Share Price & Price History
Current Price: $4.81
Price Change: ▲ Price Increase of +0.3 (6.66%)
As of 08/12/2022 01:00 AM ET
Potential 500% Return From A Unique $1 Asset?
Millions are rushing towards life at “Ground Zero”.
A frightening new financial reality that has the potential to erase the wealth of millions. It’s largely avoidable if you know what to look for.
It all hinges on a single $1 asset that skyrockets during strange times like these.
Discover it now
Delcath Systems Insider Trading History
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Shares Held After Transaction||Details|
|7/20/2022||Gerard J. Michel||CEO||Buy||62,814||$3.98||$249,999.72||125,864|| |
|5/16/2022||John Purpura||COO||Buy||3,300||$4.61||$15,213.00||27,021|| |
|5/12/2022||Steven A. J. Salamon||Director||Buy||6,000||$4.90||$29,400.00||29,424|| |
|4/19/2022||Steven A. J. Salamon||Director||Buy||1,600||$6.25||$10,000.00||429,100|| |
|4/18/2022||Gerard J. Michel||Insider||Buy||2,000||$6.37||$12,740.00||63,050|| |
|4/12/2022||Rosalind Advisors, Inc.||Director||Buy||2,500||$6.48||$16,200.00||428,000|| |
|4/11/2022||John Purpura||COO||Buy||5,000||$6.59||$32,950.00||23,721|| |
|4/8/2022||Gerard J. Michel||Insider||Buy||2,000||$6.57||$13,140.00||61,050|| |
|4/6/2022||Rosalind Advisors, Inc.||Director||Buy||1,000||$6.49||$6,490.00|| |
|12/2/2021||Gerard J. Michel||Insider||Buy||23,200||$8.61||$199,752.00|| |
|6/30/2021||Steven A. J. Salamon||Director||Buy||5,500||$12.76||$70,180.00|| |
|6/28/2021||Gerard J. Michel||CEO||Buy||6,250||$11.93||$74,562.50||29,600|| |
|6/28/2021||Steven A. J. Salamon||Director||Buy||5,000||$11.56||$57,800.00|| |
|6/25/2021||Gerard J. Michel||CEO||Buy||6,600||$11.35||$74,910.00||29,600|| |
|6/24/2021||Steven A. J. Salamon||Director||Buy||4,500||$10.90||$49,050.00|| |
|5/13/2021||John Purpura||COO||Buy||4,000||$9.42||$37,680.00||18,713|| |
|4/5/2021||Gerard J. Michel||CEO||Buy||15,500||$12.88||$199,640.00||23,000|| |
|12/11/2020||Gerard J. Michel||CEO||Buy||7,500||$13.25||$99,375.00||7,500|| |
|11/16/2020||Gil Aharon||Director||Buy||2,000||$12.00||$24,000.00|| |
|11/13/2020||Steven A. J. Salamon||Director||Buy||2,000||$11.51||$23,020.00|| |
The Safest Option in Trades!
If you’re new to trading, then you’ve probably heard the wrong thing about options—that they’re risky, unpredictable, or difficult.
And it couldn’t be more wrong! With the Hughes Optioneering Strategy, you’ll soon learn that the safest option for new accounts is options themselves!
Click here now!
Delcath Systems Institutional Trading History
Data available starting January 2016
|Reporting Date||Hedge Fund||Shares Held||Market Value||% of Portfolio||Quarterly Change in Shares||Ownership in Company||Details|
|8/10/2022||Cibc World Market Inc.||83,751||$0.33M||0.0%||-5.6%||1.059%|
|5/13/2022||Vanguard Group Inc.||360,900||$2.31M||0.0%||+5.7%||4.563%|
|5/13/2022||Dimensional Fund Advisors LP||11,793||$75K||0.0%||N/A||0.149%|
|5/12/2022||Cibc World Market Inc.||88,751||$0.57M||0.0%||+4.0%||1.122%|
|5/12/2022||CI Investments Inc.||87,367||$0.56M||0.0%||N/A||1.105%|
|2/15/2022||CIBC World Markets Inc.||85,319||$0.66M||0.0%||N/A||1.160%|
|11/16/2021||Schonfeld Strategic Advisors LLC||81,600||$0.85M||0.0%||-6.0%||1.109%|
|8/16/2021||Squarepoint Ops LLC||24,773||$0.31M||0.0%||+90.6%||0.337%|
|8/16/2021||Schonfeld Strategic Advisors LLC||86,800||$1.10M||0.0%||-20.5%||1.180%|
|8/13/2021||Northern Trust Corp||12,743||$0.16M||0.0%||N/A||0.173%|
|8/13/2021||Geode Capital Management LLC||58,722||$0.74M||0.0%||+46.6%||0.836%|
|8/12/2021||Advisory Services Network LLC||3,150||$40K||0.0%||N/A||0.045%|
|5/18/2021||Alyeska Investment Group L.P.||36,148||$0.45M||0.0%||-27.1%||0.559%|
|5/18/2021||Silverarc Capital Management LLC||40,000||$0.50M||0.3%||-88.6%||0.618%|
|5/17/2021||Schonfeld Strategic Advisors LLC||109,235||$1.36M||0.0%||N/A||1.688%|
|5/17/2021||Ikarian Capital LLC||43,915||$0.55M||0.0%||-61.0%||0.679%|
|5/17/2021||Goldman Sachs Group Inc.||10,097||$0.13M||0.0%||N/A||0.156%|
|5/13/2021||Renaissance Technologies LLC||15,900||$0.20M||0.0%||-84.3%||0.254%|
|5/12/2021||Geode Capital Management LLC||40,044||$0.50M||0.0%||+50.7%||0.641%|
|5/12/2021||MYDA Advisors LLC||20,000||$0.25M||0.1%||N/A||0.320%|
|2/24/2021||Alyeska Investment Group L.P.||49,603||$0.89M||0.0%||N/A||1.205%|
|2/18/2021||Verition Fund Management LLC||30,000||$0.54M||0.0%||N/A||0.729%|
|2/16/2021||Silverarc Capital Management LLC||351,616||$6.30M||3.7%||N/A||8.541%|
|2/16/2021||Squarepoint Ops LLC||13,563||$0.24M||0.0%||-45.6%||0.329%|
|2/16/2021||Alyeska Investment Group L.P.||49,603||$0.89M||0.0%||N/A||1.205%|
|2/16/2021||Pura Vida Investments LLC||65,000||$1.17M||0.0%||N/A||1.579%|
|2/12/2021||AWM Investment Company Inc.||87,000||$1.56M||0.2%||N/A||2.113%|
|2/12/2021||Ikarian Capital LLC||112,712||$2.02M||0.1%||+19.9%||2.738%|
|2/10/2021||Renaissance Technologies LLC||101,276||$1.82M||0.0%||N/A||2.460%|
|11/16/2020||Squarepoint Ops LLC||24,931||$0.29M||0.0%||+43.9%||0.610%|
|11/16/2020||Worth Venture Partners LLC||22,598||$0.26M||0.2%||-11.4%||0.553%|
|8/14/2020||Worth Venture Partners LLC||25,500||$0.26M||0.1%||N/A||0.655%|
|8/14/2020||Ikarian Capital LLC||94,000||$0.96M||0.1%||N/A||2.414%|
|8/12/2020||Hudson Bay Capital Management LP||88,678||$0.91M||0.0%||N/A||2.277%|
Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan hydrochloride for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. Its clinical development program for HEPZATO is the FOCUS clinical trial for patients with hepatic dominant ocular melanoma to investigate objective response rate in metastatic ocular melanoma. The company also provides HEPZATO as a stand-alone medical device for sale under the CHEMOSAT Hepatic Delivery System for Melphalan trade name for medical centers to treat a range of liver cancers in Europe. Delcath Systems, Inc. was incorporated in 1988 and is headquartered in New York, New York.
50 Day Range
52 Week Range
Who are the company insiders with the largest holdings of Delcath Systems?
Delcath Systems' top insider shareholders include:
Learn More about top insider investors at Delcath Systems.
- Steven A J Salamon (Director)
- Rosalind Advisors, Inc (Director)
- Gerard J Michel (CEO)
- Gerard J Michel (Insider)
- John Purpura (COO)
- Ernest C Garcia II (Major Shareholder)
- Gil Aharon (Director)
Who are the major institutional investors of Delcath Systems?
Which major investors are selling Delcath Systems stock?
In the last quarter, DCTH stock was sold by these institutional investors:
- Cibc World Market Inc.